Leap Therapeutics (LPTX) Competitors $0.48 0.00 (-0.52%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$0.48 +0.00 (+0.17%) As of 02/21/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends LPTX vs. EPIX, FBRX, AVTX, APLT, BGM, INCR, MURA, GANX, PMVP, and IKNAShould you be buying Leap Therapeutics stock or one of its competitors? The main competitors of Leap Therapeutics include ESSA Pharma (EPIX), Forte Biosciences (FBRX), Avalo Therapeutics (AVTX), Applied Therapeutics (APLT), Qilian International Holding Group (BGM), InterCure (INCR), Mural Oncology (MURA), Gain Therapeutics (GANX), PMV Pharmaceuticals (PMVP), and Ikena Oncology (IKNA). These companies are all part of the "pharmaceutical products" industry. Leap Therapeutics vs. ESSA Pharma Forte Biosciences Avalo Therapeutics Applied Therapeutics Qilian International Holding Group InterCure Mural Oncology Gain Therapeutics PMV Pharmaceuticals Ikena Oncology Leap Therapeutics (NASDAQ:LPTX) and ESSA Pharma (NASDAQ:EPIX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, community ranking, dividends, analyst recommendations, institutional ownership and valuation. Is LPTX or EPIX more profitable? ESSA Pharma's return on equity of -24.61% beat Leap Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Leap TherapeuticsN/A -116.24% -93.18% ESSA Pharma N/A -24.61%-23.87% Which has better valuation & earnings, LPTX or EPIX? ESSA Pharma is trading at a lower price-to-earnings ratio than Leap Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLeap TherapeuticsN/AN/A-$81.41M-$1.93-0.25ESSA PharmaN/AN/A-$28.54M-$0.69-2.49 Does the MarketBeat Community favor LPTX or EPIX? ESSA Pharma received 55 more outperform votes than Leap Therapeutics when rated by MarketBeat users. Likewise, 75.87% of users gave ESSA Pharma an outperform vote while only 68.53% of users gave Leap Therapeutics an outperform vote. CompanyUnderperformOutperformLeap TherapeuticsOutperform Votes29468.53% Underperform Votes13531.47% ESSA PharmaOutperform Votes34975.87% Underperform Votes11124.13% Does the media prefer LPTX or EPIX? In the previous week, ESSA Pharma had 18 more articles in the media than Leap Therapeutics. MarketBeat recorded 18 mentions for ESSA Pharma and 0 mentions for Leap Therapeutics. ESSA Pharma's average media sentiment score of 0.08 beat Leap Therapeutics' score of 0.00 indicating that ESSA Pharma is being referred to more favorably in the news media. Company Overall Sentiment Leap Therapeutics Neutral ESSA Pharma Neutral Which has more volatility & risk, LPTX or EPIX? Leap Therapeutics has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500. Comparatively, ESSA Pharma has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500. Do institutionals & insiders have more ownership in LPTX or EPIX? 30.5% of Leap Therapeutics shares are owned by institutional investors. Comparatively, 75.1% of ESSA Pharma shares are owned by institutional investors. 5.4% of Leap Therapeutics shares are owned by company insiders. Comparatively, 15.5% of ESSA Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts recommend LPTX or EPIX? Leap Therapeutics presently has a consensus price target of $4.92, suggesting a potential upside of 923.88%. ESSA Pharma has a consensus price target of $9.50, suggesting a potential upside of 452.33%. Given Leap Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Leap Therapeutics is more favorable than ESSA Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Leap Therapeutics 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25ESSA Pharma 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryESSA Pharma beats Leap Therapeutics on 11 of the 14 factors compared between the two stocks. Get Leap Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LPTX vs. The Competition Export to ExcelMetricLeap TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$18.50M$7.05B$5.82B$9.09BDividend YieldN/A2.76%4.77%3.84%P/E RatioN/A3.1618.9215.38Price / SalesN/A311.68453.2984.08Price / CashN/A67.2843.8437.22Price / Book0.206.717.644.65Net Income-$81.41M$138.11M$3.18B$245.69M7 Day Performance-4.67%-2.54%-1.95%-2.67%1 Month Performance-79.12%-2.00%-0.23%-2.16%1 Year Performance-83.94%-5.04%16.69%12.90% Leap Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LPTXLeap Therapeutics1.3631 of 5 stars$0.48-0.5%$4.92+923.9%-84.0%$18.50MN/A0.0040EPIXESSA Pharma3.1167 of 5 stars$1.73-0.6%$9.50+449.1%-79.0%$76.80MN/A-2.7050High Trading VolumeFBRXForte Biosciences3.4697 of 5 stars$12.00+7.6%$23.58+96.5%+39,891.3%$76.68MN/A-0.745Options VolumeNews CoverageAVTXAvalo Therapeutics3.366 of 5 stars$7.35-4.9%$40.00+444.2%+94.9%$76.40M$820,000.000.0040Analyst ForecastNews CoverageGap UpAPLTApplied Therapeutics4.6863 of 5 stars$0.65+9.2%$6.10+842.8%-89.7%$75.29M$9.99M-0.4030BGMQilian International Holding GroupN/A$10.28-0.8%N/AN/A$74.32M$25.10M0.00298INCRInterCure0.3593 of 5 stars$1.62+0.6%N/A-15.0%$73.83M$272.67M0.00350News CoverageMURAMural Oncology3.6059 of 5 stars$4.29+0.7%$16.00+273.0%-13.6%$73.02MN/A-0.47119GANXGain Therapeutics2.1425 of 5 stars$2.73+6.6%$7.25+165.6%-48.6%$72.40M$50,000.00-2.4820Gap UpPMVPPMV Pharmaceuticals2.5634 of 5 stars$1.39-2.1%$5.50+295.7%-16.6%$71.93MN/A-1.3950Positive NewsIKNAIkena Oncology3.4025 of 5 stars$1.49-2.6%$3.00+101.3%+4.5%$71.90M$659,000.00-1.2170Positive NewsHigh Trading Volume Related Companies and Tools Related Companies ESSA Pharma Alternatives Forte Biosciences Alternatives Avalo Therapeutics Alternatives Applied Therapeutics Alternatives Qilian International Holding Group Alternatives InterCure Alternatives Mural Oncology Alternatives Gain Therapeutics Alternatives PMV Pharmaceuticals Alternatives Ikena Oncology Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LPTX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | SponsoredWarning: China Launches AI Attack on AmericaIf you have any money in AI stocks, pay attention because... According to Louis Navellier, the legendary in...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Leap Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Leap Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
